Public Comment Period on Pharmaceutical Mergers Opens and Exposes Dueling Philosophies Among FTC Commissioners
By EsqSocial Corporation 21/05/21
The Multilateral Pharmaceutical Merger Task Force, a working group formed by the Federal Trade Commission (“FTC”), the Antitrust Division of the Department of Justice, State Attorneys General, and counterpart enforcement agencies in Europe and the UK, recently opened a comment period soliciting public input regarding how pharmaceutical mergers should be analyzed, including new potential theories of harm, market definition, and appropriate remedies. The comment period lasts until June 25, 2021....
By: Epstein Becker & Green